2 results  1 of 1 

1 The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication
Hyuk-Sang Kwon
J Korean Diabetes.2016;17(4):225-232.   Published online 2016 January 10     DOI: http://dx.doi.org/10.4093/jkd.2016.17.4.225
   
2 A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Chang Hee Jung, Jung Eun Jang, Joong-Yeol Park
Diabetes Metab J.2014;38(4):261-273.   Published online 2014 August 20     DOI: http://dx.doi.org/10.4093/dmj.2014.38.4.261
      

 1 of 1